Home
MLTX
MLTX News

Latest MoonLake Immunotherapeutics (MLTX) News on June 3, 2025

Newsfile

4 days ago

Sienna Resources Inc. Announces Private Placement

Energy Global

4 days ago

European Energy completes sale of Polish wind portfolio to Enea Group

Newsfile

4 days ago

Carbone Restaurant Group is a GOLD Sponsor at the Centurion One Capital 6th Annual LA Summit

Newsfile

4 days ago

Max Resource Corp. Announces Participation in THE Mining Investment Event, Quebec City, June 3-5, 2025

First Foundation Bank review (2025): Personal and business banking with competitive online rates

Yahoo Personal Finance

4 days ago

First Foundation Bank review (2025): Personal and business banking with competitive online rates

Investing.com

4 days ago

Airbnb shares dip as Truist cuts stock to Sell on weak summer trends, valuation

Report: Slower economy doesn't dim downtown Austin's dynamism

Austin American-Statesman

4 days ago

Report: Slower economy doesn't dim downtown Austin's dynamism

Nvidia (NVDA) Gets Wall Street Boost on Strong Q1 Results and Upbeat Guidance

GuruFocus.com

4 days ago

Nvidia (NVDA) Gets Wall Street Boost on Strong Q1 Results and Upbeat Guidance

H.C. Wainwright Maintains Buy Rating on MoonLake Immunotherapeutics (MLXT), Keeps PT

Insider Monkey

7 days ago

H.C. Wainwright Maintains Buy Rating on MoonLake Immunotherapeutics (MLXT), Keeps PT

MT Newswires

15 days ago

Wolfe Research Upgrades MoonLake Immunotherapeutics to Outperform From Peer Perform

Wall Street Analysts Think MOONLAKE IMMUNO (MLTX) Could Surge 106.62%: Read This Before Placing a Bet

Zacks

19 days ago

Wall Street Analysts Think MOONLAKE IMMUNO (MLTX) Could Surge 106.62%: Read This Before Placing a Bet

MT Newswires

21 days ago

Wedbush Adjusts Price Target on MoonLake Immunotherapeutics to $80 From $78, Maintains Outperform Rating

MT Newswires

22 days ago

MoonLake Immunotherapeutics Q1 Loss Widens

MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update

GlobeNewswire

22 days ago

MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29

GlobeNewswire

a month ago

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29

Is MoonLake Immunotherapeutics (MLTX) Among the Best Guru Stocks to Buy According to Wall Street Analysts?

Insider Monkey

a month ago

Is MoonLake Immunotherapeutics (MLTX) Among the Best Guru Stocks to Buy According to Wall Street Analysts?

MT Newswires

2 months ago

MoonLake Obtains $500 Million Facility From Hercules Capital

MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates

GlobeNewswire

2 months ago

MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates

MT Newswires

3 months ago

Correction: RBC Initiates MoonLake Immunotherapeutics at Outperform, Speculative Risk With $67 Price Target

MT Newswires

3 months ago

RBC Initiates MoonLake Immunotherapeutics at Outperform, Speculative Risk With $17 Price Target

MT Newswires

3 months ago

MoonLake Immunotherapeutics Q4 Loss Widens

MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update

GlobeNewswire

3 months ago

MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update

Is MoonLake Immunotherapeutics (MLTX) An Oversold Biotech Stock to Buy Now?

Insider Monkey

3 months ago

Is MoonLake Immunotherapeutics (MLTX) An Oversold Biotech Stock to Buy Now?

MoonLake Immunotherapeutics (MLTX): the Most Oversold Pharma Stock to Buy According to Analysts

Insider Monkey

3 months ago

MoonLake Immunotherapeutics (MLTX): the Most Oversold Pharma Stock to Buy According to Analysts

MoonLake Immunotherapeutics (MLTX): Among the Most Oversold Healthcare Stocks to Buy Now

Insider Monkey

3 months ago

MoonLake Immunotherapeutics (MLTX): Among the Most Oversold Healthcare Stocks to Buy Now

We're Hopeful That MoonLake Immunotherapeutics (NASDAQ:MLTX) Will Use Its Cash Wisely

Simply Wall St.

4 months ago

We're Hopeful That MoonLake Immunotherapeutics (NASDAQ:MLTX) Will Use Its Cash Wisely

MT Newswires

5 months ago

Goldman Sachs Upgrades MoonLake Immunotherapeutics to Buy From Neutral, Adjusts Price Target to $82 From $62

MoonLake Immunotherapeutics price target raised to $81 from $71 at BTIG

TipRanks

5 months ago

MoonLake Immunotherapeutics price target raised to $81 from $71 at BTIG

MT Newswires

5 months ago

BTIG Adjusts MoonLake Immunotherapeutics' Price Target to $81 From $71, Keeps Buy Rating

MT Newswires

5 months ago

MoonLake's Three New Trials Will Expand Sonelokimab's Potential, Wedbush Says

MT Newswires

5 months ago

MoonLake Immunotherapeutics Starts Three New Clinical Trials Evaluating Sonelokimab in Inflammatory Diseases

MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab

GlobeNewswire

5 months ago

MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab

Is There An Opportunity With MoonLake Immunotherapeutics' (NASDAQ:MLTX) 27% Undervaluation?

Simply Wall St.

5 months ago

Is There An Opportunity With MoonLake Immunotherapeutics' (NASDAQ:MLTX) 27% Undervaluation?

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis

GlobeNewswire

7 months ago

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis

MT Newswires

7 months ago

MoonLake Immunotherapeutics' Q3 Net Loss Widens

MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update

GlobeNewswire

7 months ago

MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update

Argus Research

8 months ago

Daily – Vickers Top Buyers & Sellers for 10/09/2024

GuruFocus.com

8 months ago

Biotechnology Value Fund L.P. Reduces Stake in MoonLake Immunotherapeutics

MT Newswires

8 months ago

Moonlake Immunotherapeutics Insider Sold Shares Worth $9,186,120, According to a Recent SEC Filing

Is MoonLake Immunotherapeutics (MLTX) the Best Guru Stock To Buy Now?

Insider Monkey

8 months ago

Is MoonLake Immunotherapeutics (MLTX) the Best Guru Stock To Buy Now?

MoonLake Immunotherapeutics (MLTX): Short Seller Sentiment is Bearish On This ADR Stock

Insider Monkey

8 months ago

MoonLake Immunotherapeutics (MLTX): Short Seller Sentiment is Bearish On This ADR Stock

MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11

GlobeNewswire

9 months ago

MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11

MoonLake Immunotherapeutics (MLTX): One of Oppenheimer’s Top Stock Picks For the Next 12 Months

Insider Monkey

9 months ago

MoonLake Immunotherapeutics (MLTX): One of Oppenheimer’s Top Stock Picks For the Next 12 Months

MT Newswires

9 months ago

MoonLake Immunotherapeutics Shares Fall After Wolfe Research Downgrade

MT Newswires

9 months ago

Wolfe Research Downgrades MoonLake Immunotherapeutics to Peer Perform From Outperform

We're Interested To See How MoonLake Immunotherapeutics (NASDAQ:MLTX) Uses Its Cash Hoard To Grow

Simply Wall St.

9 months ago

We're Interested To See How MoonLake Immunotherapeutics (NASDAQ:MLTX) Uses Its Cash Hoard To Grow

MT Newswires

10 months ago

MoonLake Immunotherapeutics Shares Slightly Up Despite Wider Q2 Loss

MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11

GlobeNewswire

10 months ago

MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11

MT Newswires

a year ago

Oppenheimer Initiates MoonLake Immunotherapeutics at Outperform With $104 Price Target

$6.6 Billion Digital X-ray Market, 2024-2029: Development of AI-based Digital X-Ray Systems Present Business Opportunities

GlobeNewswire

a year ago

$6.6 Billion Digital X-ray Market, 2024-2029: Development of AI-based Digital X-Ray Systems Present Business Opportunities

2 Reasons to Buy Rivian Stock (and 1 Big Reason to Sell)

Motley Fool

a year ago

2 Reasons to Buy Rivian Stock (and 1 Big Reason to Sell)

DFR Gold Inc. Announces Amendment of WUO Land Option and Insider Loans

CNW Group

a year ago

DFR Gold Inc. Announces Amendment of WUO Land Option and Insider Loans

Walmart Stock Climbs After Dow Jones Giant Receives Upgrade, Major Price Target Hike

Investor's Business Daily

a year ago

Walmart Stock Climbs After Dow Jones Giant Receives Upgrade, Major Price Target Hike

EPCOR and HAWSCo Enter Ownership Transfer Agreement

CNW Group

a year ago

EPCOR and HAWSCo Enter Ownership Transfer Agreement

Video on Demand (VoD) Market Report 2024-2034: Netflix, Amazon, Google and Hulu Dominate

GlobeNewswire

a year ago

Video on Demand (VoD) Market Report 2024-2034: Netflix, Amazon, Google and Hulu Dominate

Southwest Airlines stock pops on report of Elliott's $2B stake

Yahoo Finance Video

a year ago

Southwest Airlines stock pops on report of Elliott's $2B stake

Business Wire

a year ago

Form 8.3 - Virgin Money UK plc

MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis

GlobeNewswire

a year ago

MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis

MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa

GlobeNewswire

a year ago

MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa

GuruFocus.com

a year ago

MoonLake Immunotherapeutics Reports Q1 2024 Financial Outcomes

MT Newswires

a year ago

MoonLake Immunotherapeutics Q1 Net Loss Widens

MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update

GlobeNewswire

a year ago

MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions

Business Wire

a year ago

MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions

MoonLake Immunotherapeutics (NASDAQ:MLTX) Is In A Strong Position To Grow Its Business

Simply Wall St.

a year ago

MoonLake Immunotherapeutics (NASDAQ:MLTX) Is In A Strong Position To Grow Its Business

MoonLake Jumps After Arthritis Drug Tops AbbVie Blockbuster Humira In A Key Test

Investor's Business Daily

a year ago

MoonLake Jumps After Arthritis Drug Tops AbbVie Blockbuster Humira In A Key Test

MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day

GlobeNewswire

a year ago

MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day

MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024

GlobeNewswire

a year ago

MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024

Insider Sell: CEO Santos da Silva Jorge Sells 123,615 Shares of MoonLake Immunotherapeutics (MLTX)

GuruFocus.com

a year ago

Insider Sell: CEO Santos da Silva Jorge Sells 123,615 Shares of MoonLake Immunotherapeutics (MLTX)

MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10

GlobeNewswire

a year ago

MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10

MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)

GlobeNewswire

a year ago

MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)

Insider Sell: CEO Santos da Silva Jorge Sells 60,000 Shares of MoonLake Immunotherapeutics

GuruFocus.com

a year ago

Insider Sell: CEO Santos da Silva Jorge Sells 60,000 Shares of MoonLake Immunotherapeutics

Beazer Homes (BZH) Q1 Earnings & Revenues Miss, Orders Up

Zacks

a year ago

Beazer Homes (BZH) Q1 Earnings & Revenues Miss, Orders Up

Zurn Elkay Water Solutions Declares Quarterly Cash Dividend

Business Wire

a year ago

Zurn Elkay Water Solutions Declares Quarterly Cash Dividend

Why Fast-paced Mover Celestica (CLS) Is a Great Choice for Value Investors

Zacks

a year ago

Why Fast-paced Mover Celestica (CLS) Is a Great Choice for Value Investors

Noble Corporation plc announces changes to its share capital for the month of January 2024

PR Newswire

a year ago

Noble Corporation plc announces changes to its share capital for the month of January 2024

Rush Enterprises, Inc. Conference Call Advisory for Fourth Quarter and Year-End 2023 Earnings Results

GlobeNewswire

a year ago

Rush Enterprises, Inc. Conference Call Advisory for Fourth Quarter and Year-End 2023 Earnings Results

Argus Research

a year ago

Daily – Vickers Top Buyers & Sellers for 01/31/2024

Director John Schultz Acquires 8,559 Shares of Columbia Banking System Inc

GuruFocus.com

a year ago

Director John Schultz Acquires 8,559 Shares of Columbia Banking System Inc

Is Janus Henderson Enterprise I (JMGRX) a Strong Mutual Fund Pick Right Now?

Zacks

a year ago

Is Janus Henderson Enterprise I (JMGRX) a Strong Mutual Fund Pick Right Now?

VNT vs. VLTO: Which Stock Should Value Investors Buy Now?

Zacks

a year ago

VNT vs. VLTO: Which Stock Should Value Investors Buy Now?

A Motley Fool Co-Founder's Roller-Coaster Nvidia Story

Motley Fool

a year ago

A Motley Fool Co-Founder's Roller-Coaster Nvidia Story

Automotive Telematics Market to Exceed USD 34.52 billion by 2031 | According to Transparency Market Research Analysis

GlobeNewswire

a year ago

Automotive Telematics Market to Exceed USD 34.52 billion by 2031 | According to Transparency Market Research Analysis

3 Asset Management Stocks Set to Pull Off Earnings Beat in Q4

Zacks

a year ago

3 Asset Management Stocks Set to Pull Off Earnings Beat in Q4

Novo Nordisk Puts Pharma Peers in the Shade as Key Earnings Reports Awaited

Bloomberg

a year ago

Novo Nordisk Puts Pharma Peers in the Shade as Key Earnings Reports Awaited

MAG Silver (MAG) Reports Solid Production at Juanicipio

Zacks

a year ago

MAG Silver (MAG) Reports Solid Production at Juanicipio

19 Best Reusable Water Bottles on Amazon Under $50

Insider Monkey

a year ago

19 Best Reusable Water Bottles on Amazon Under $50

Are You Looking for a High-Growth Dividend Stock?

Zacks

a year ago

Are You Looking for a High-Growth Dividend Stock?

Business Wire

a year ago

Webster Financial Corporation Declares Common and Preferred Dividends

Here's Why Transocean (RIG) Fell More Than Broader Market

Zacks

a year ago

Here's Why Transocean (RIG) Fell More Than Broader Market

Reasons to Add Blueprint (BPMC) Stock to Your Portfolio Now

Zacks

a year ago

Reasons to Add Blueprint (BPMC) Stock to Your Portfolio Now

Colliers to announce fourth quarter and full year results on February 8, 2024

GlobeNewswire

a year ago

Colliers to announce fourth quarter and full year results on February 8, 2024

Cytokinetics Stock Drops After Journal Report That Novartis Deal Might Be Off

The Wall Street Journal

a year ago

Cytokinetics Stock Drops After Journal Report That Novartis Deal Might Be Off

Wall Street Analysts Believe MoonLake Immunotherapeutics (MLTX) Could Rally 26.97%: Here's is How to Trade

Zacks

a year ago

Wall Street Analysts Believe MoonLake Immunotherapeutics (MLTX) Could Rally 26.97%: Here's is How to Trade

Is MoonLake Immunotherapeutics (MLTX) Stock a Solid Choice Right Now?

Zacks

a year ago

Is MoonLake Immunotherapeutics (MLTX) Stock a Solid Choice Right Now?

Labcorp and Hawthorne Effect Collaborate to Bring Clinical Trials Directly to Patients and Investigators in Local Communities

PR Newswire

a year ago

Labcorp and Hawthorne Effect Collaborate to Bring Clinical Trials Directly to Patients and Investigators in Local Communities

Armstrong World (AWI) Enters Strategic Pact, Invests in Overcast

Zacks

a year ago

Armstrong World (AWI) Enters Strategic Pact, Invests in Overcast

New Strong Buy Stocks for January 5th

Zacks

a year ago

New Strong Buy Stocks for January 5th

InvestorPlace

a year ago

Why Do Shipping Stocks Gain in Times of Geopolitical Crisis?

Here's Why Investors Should Retain Paychex (PAYX) Stock Now

Zacks

a year ago

Here's Why Investors Should Retain Paychex (PAYX) Stock Now

Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones

GlobeNewswire

a year ago

Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones

Share on Social Networks: